Holen Sie sich die Stockscreener-App
10.27
9.50%
0.80
Schlusskurs vom Vortag:
$9.47
Offen:
$9.48
24-Stunden-Volumen:
200.14K
Relative Volume:
0.16
Marktkapitalisierung:
$554.44M
Einnahmen:
$2.80M
Nettoeinkommen (Verlust:
$-122.23M
KGV:
-4.4965
EPS:
-2.284
Netto-Cashflow:
$-46.53M
1W Leistung:
+23.74%
1M Leistung:
+31.26%
6M Leistung:
-39.92%
1J Leistung:
+51.60%
1-Tages-Spanne:
$9.38
$10.43
1-Wochen-Bereich:
$8.12
$10.40
52-Wochen-Spanne:
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
10.26 | 511.75M | 2.80M | -122.23M | -46.53M | -2.284 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.85 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.68 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
694.36 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.91 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
UPB: Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027 - TradingView
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027 - Investing.com
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug - Traders Union
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Upstream Bio plans two late-stage trials for asthma, nasal polyps in 2027 - Stock Titan
Upstream Bio (NASDAQ:UPB) Trading Up 11.2%What's Next? - MarketBeat
Gainers Report: Is Upstream Bio Inc still a buy after recent gains2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Aug EndMonth: What is the next catalyst for Upstream Bio IncMarket Trend Report & Stock Timing and Entry Methods - baoquankhu1.vn
Upstream Bio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares - Investing.com
Upstream Bio CFO Gray sells $7915 in shares By Investing.com - Investing.com South Africa
Upstream Bio CEO Makes Notable Move With Fresh Stock Sale - TipRanks
Upstream Bio (UPB) CFO executes automatic share sale to cover RSU taxes - Stock Titan
Upstream Bio (UPB) CMO auto-sells 894 shares to cover RSU taxes - Stock Titan
Tax-related sale: Upstream Bio (UPB) CEO automatically sells 2,093 shares - Stock Titan
Tax-withholding share sale by Upstream Bio (UPB) General Counsel disclosed - Stock Titan
Tax-related stock sale by Upstream Bio (UPB) chief business officer - Stock Titan
Risk Recap: Whats next for Upstream Bio Inc stockM&A Rumor & Short-Term Swing Trade Alerts - baoquankhu1.vn
Integral Health Asset Management LLC Acquires New Stake in Upstream Bio, Inc. $UPB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 14.4% HigherShould You Buy? - MarketBeat
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing - TradingView
UPB: Verekitug's quarterly dosing shows robust efficacy, with phase 3 and COPD programs advancing - TradingView
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference - Traders Union
Dip Buying: Is Upstream Bio Inc forming a breakout pattern2025 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Upstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concerns - MSN
Aug Sectors: Can Upstream Bio Inc deliver consistent dividendsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Lifesci Capital Forecasts Upstream Bio Q2 Earnings - MarketBeat
Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25 - Defense World
Why Did UPB Stock Plunge 40% Today? - Stocktwits
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio presents additional Phase 2 data for verekitug - Investing.com South Africa
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com Canada
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Upstream Bio Inc-Aktie (UPB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):